Objective: We aimed to determine the frequency of probable obstructive sleep apnea (pOSA) in refractory epilepsy monitoring unit inpatients and clinical features associated with pOSA, including risk for sudden unexpected death in epilepsy (SUDEP). Methods: We prospectively recruited 49 consecutive adult patients admitted to the Mayo Clinic Epilepsy Monitoring Unit with focal, generalized, or unclassified epilepsy syndromes. pOSA was identified using oximetric oxyhemoglobin desaturation index (ODI) and the Sleep Apnea-Sleep Disorders Questionnaire (SA-SDQ) and STOP-BAG screening tools. Revised SUDEP Risk Inventory (rSUDEP-7) scores were calculated, and epilepsy patients with and without pOSA were compared with Wilcoxon signed-rank tests. Correlation and regression analyses were utilized to determine relationships between pOSA and rSU-DEP-7 scores. Results: Thirty-five percent of patients had pOSA, with a mean ODI of 11.3 ± 5.1/h (range = 5.1-22.8). Patients with pOSA were older and heavier, and more frequently had a focal epilepsy syndrome and longer epilepsy duration, with higher SA-SDQ and STOP-BAG scores (all P < 0.05). Median rSUDEP-7 score was 3 ± 1.4 (range = 0-6). Higher rSUDEP-7 scores were positively correlated with higher ODI (P = 0.036). rSUDEP-7 score ≥ 5 was associated with pOSA by ODI, SA-SDQ, and STOP-BAG questionnaire criteria (P < 0.05). Significance: Our pilot study identified a high frequency of pOSA in refractory epilepsy monitoring patients, finding that pOSA patients were older and heavier, with higher screening symptoms for sleep apnea and more frequent focal seizures with a longer epilepsy duration. We also found a possible association between OSA and SUDEP risk. Identification and treatment of OSA in patients with epilepsy could conceivably provide a novel approach toward preventing the risk of SUDEP. Future studies with polysomnography are needed to confirm predictive
| INTRODUCTION
People with epilepsy have a 20-fold heightened risk for sudden death relative to the general population. 1 Sudden unexpected death in epilepsy (SUDEP) is the main cause of potentially avoidable, epilepsy-related deaths. SUDEP is defined as sudden, unexpected, and nontraumatic death in patients with epilepsy in whom autopsy does not reveal a structural or toxic cause for death. 2 SUDEP may occur with or without evidence of a preceding seizure, with exclusion of documented status epilepticus. Estimates of SUDEP incidence range from 0.09 to 9.3 per 1000 persons. 3 However, in those with refractory epilepsy, SUDEP yields an estimated 35% lifetime risk. 4 Mechanisms underlying SUDEP deaths remain largely unknown, although several risk factors have been identified. 5 Although it has not yet been validated in large-scale epilepsy populations, the SUDEP Risk Inventory (SUDEP-7) has been proposed to quantify SUDEP risk in living people with epilepsy based upon five factors: frequency of generalized tonicclonic seizures, monthly seizure frequency, number of antiepileptic drugs in use, duration of epilepsy, and intellectual disability. Each risk factor is assigned a point score based on its respective odds ratio for SUDEP, with a possible score of 0-12. 6 The revised SUDEP-7 (rSUDEP-7)
combines generalized tonic-clonic seizures and seizure frequency measures to reduce score inflation (Table 1) . 7 SUDEP is believed to most often occur in the periictal state; however, its pathophysiology remains to be elucidated. The major mechanisms proposed to underlie SUDEP are cardiac, respiratory, or cerebral dysfunction, or a combination of overlapping contributions from these pathways. 8 Previous research has demonstrated associations between T A B L E 1 Comparing the SUDEP-7 to the revised SUDEP-7
Risk factor
Odds ratio SUDEP-7 Revised SUDEP-7 
Key Points
• Obstructive sleep apnea is common in monitored epilepsy inpatients • Epilepsy patients with probable OSA were older and heavier, and more frequently had focal seizures and a longer duration of epilepsy • Higher revised SUDEP-7 scores are associated with probable OSA • Additional confirmatory studies with polysomnography are needed to determine whether OSA is associated with SUDEP risk elevated SUDEP-7 score and candidate contributors to SUDEP pathophysiology including cerebral hypoxemia, 9 reduced heart rate variability, 6 and postictal generalized electroencephalographic suppression. 10 In cases of witnessed SUDEP, the consistent predominant fatal pattern was a generalized tonic-clonic seizure followed by a period of centrally mediated respiratory and cardiac dysfunction, then followed variably by either cardiorespiratory arrest and death, or a terminal brief partial restoration of cardiac rhythm prior to terminal apnea and cardiac arrest. Terminal apnea superseded asystole, and 87.5% of SUDEP cases occurred during sleep, suggesting potential roles for either a sleep state-dependent influence upon SUDEP risk, and/or contributions of sleep disorders such as sleep apnea to SUDEP pathophysiology. 11 Furthermore, magnetic resonance imaging of patients at high risk for SUDEP and those who suffered SUDEP have shown an enlarged right anterior hippocampus, amygdala, and parahippocampus and reduced posterior thalamic gray matter volume. 12 These findings provide further evidence for autonomic dysfunction underlying SUDEP due to their roles in regulating sympathetic outflow to the medulla and respiratory variability in response to hypoxia, respectively. Obstructive sleep apnea (OSA) has been previously identified as an independent risk factor for sudden cardiac death (SCD) 13, 14 and is linked to cardiovascular disease, arrhythmia (including bradyarrhythmia and asystole), and increased mortality. 15, 16 The frequency of comorbid OSA in various epilepsy cohorts has been estimated to range between approximately 10% and 30%, and is more frequent in those with refractory epilepsy. [17] [18] [19] [20] Although it is unclear whether the association between SCD and OSA is relevant to the likely distinct neurocardiorespiratory factors and events thought to mediate SUDEP, there are parallels between these entities in that both SCD and refractory epilepsy have a distinctive link to sleep, implying that OSA might promote sudden death in either case, or alternatively, that OSA may potentiate underlying risk factors and pathophysiologic factors underlying SUDEP. We aimed to determine the frequency of comorbid OSA and utility of screening instruments for detecting OSA in our refractory monitored epilepsy population, and to determine whether OSA is associated with SUDEP risk profile. 21 STOP-BAG provides a predicted score for OSA risk based on the presence or absence of the following seven criteria: a history of disruptive snoring, tiredness, observed breathing pauses, high blood pressure; and elevated body mass index (BMI; ≥35 kg/m 2 ), age > 50 years, and male sex (gender).
| MATERIALS AND METHODS
One point is scored for each present factor, and patients are classified into categories of low (0-2), intermediate (3) (4) , or high risk (5-7) for OSA. Patients with a STOP-BAG score of ≥3 were considered to have a diagnosis of pOSA. 22 For subject safety, all with positive screening scores for pOSA on questionnaires or oximetry were advised to seek clinical sleep medicine consultation and confirmatory polysomnography, although polysomnography was not a formal part of this low-resource pilot study. Demographic and epilepsy-related data concerning seizure type, frequency, duration of epilepsy, presence of absence of nocturnal seizures, presence or absence of International League Against Epilepsy-defined treatment refractory epilepsy, current antiepileptic drug treatment at the time of admission, calculated antiepileptic drug load (sum of each patient subject's antiepileptic drug daily dose, divided by that drug's World Health Organization-defined daily dosage), other data necessary for calculation of rSUDEP-7 scores, and information concerning medical comorbidities and other medications was abstracted from hospital admission notes.
| Statistical analyses
Statistical calculations were performed using JMP version 13 (SAS Institute, Cary, North Carolina). Qualitative data were reported as relative frequencies. Quantitative data were reported as means, medians, standard deviation, and range. Chi-square tests were used to compare categorical variables, whereas Wilcoxon rank-sum tests were utilized for continuous variables. Pearson correlation coefficient and multivariate regression analyses were then used to determine relationships between rSUDEP-7 scores and OSA measures. Significance level was set at an alpha of P < 0.05. Agreement between subjective (questionnaire) and objective (oximetric ODI) measures were assessed using the kappa statistic, with level of agreement specified according to standard definitions. 23 
| RESULTS
Forty-nine consecutive epilepsy subjects were analyzed, 14 (28.6%) of whom had treatment-resistant epilepsy. The group had an average age of 37. (Figure 1 ). Although all 19 subjects who screened positive were advised to pursue sleep medicine consultation and polysomnography, only three of 19 (15.8%) did so, and in these subjects OSA was confirmed, with a mean apnea-hypopnea index of 6.3/h. Comparisons between the subgroups of patients with (ODI ≥ 5/h) and without (ODI < 5/h) pOSA are also shown in Table 2 . pOSA patients by oximetric ODI ≥ 5/h had significantly higher SA-SDQ and STOP-BAG scores, were older, and were more likely to have focal epilepsy syndrome diagnosis and a longer duration of epilepsy than those who did not have pOSA by ODI (P all < 0.05). In particular, patients with at least 30 years of epilepsy had significantly higher frequency of pOSA as identified by any measure compared with patients with epilepsy for less than 30 years (P < 0.05). Agreement between STOP-BAG and ODI for pOSA diagnosis was fair (k = 0.39), whereas agreement between SA-SDQ and ODI was moderate (k = 0.45). Agreement for pOSA diagnosis was best between SA-SDQ and STOP-BAG measures (k = 0.66). Median rSUDEP-7 score was 3 (range = 0-6), with a mean of 2.9 ± 1.4. Higher rSUDEP-7 scores were associated with higher ODI values (Pearson r = 0.32, P = 0.036; Figure 2 ), and rSUDEP-7 scores > 3 were also associated with pOSA diagnosis by ODI ≥ 5/h (univariate, P = 0.036). Patients with an rSUDEP-7 score of ≥5 had higher adjusted ODI compared with scores of <5 (P = 0.007), which remained significantly associated with pOSA in multivariate analysis when adjusting for age, sex, calculated antiepileptic drug load, number of antiepileptic drugs at time of study, and BMI (P = 0.03). Patients with an rSUDEP-7 score ≥ 5 were more likely to have a diagnosis of OSA by all three measures combined (P = 0.006), as well as ODI (P = 0.01), STOP-BAG (P = 0.04), and SA-SDQ (P = 0.008), individually. There were also associations between rSUDEP-7 scores ≥ 5 and patients having a pOSA diagnosis by all three measures (oximetry, STOP-BAG, and SA-SDQ; P = 0.001). There were no associations between rSUDEP-7 score and age, sex, BMI, epilepsy type (partial vs generalized), nocturnal seizures, refractory epilepsy, or sleepiness (Table 2) . Conversely, patients with a longer duration of epilepsy had higher rSUDEP-7 scores (P = 0.008).
| DISCUSSION
pOSA was associated with rSUDEP-7 scores, and pOSA measured objectively by overnight oximetry remained associated with rSUDEP-7 scores ≥ 5, when controlling for covariates of age, sex, and BMI. Additionally, rSUDEP-7 scores ≥ 5 were associated with a pOSA by the SA-SDQ and STOP-BAG questionnaire measures. Taken together, our results suggest that OSA is likely highly prevalent in inpatients with refractory epilepsy, and may be associated with an increased risk for sudden death in patients with epilepsy, thus identifying OSA as a possible modifiable risk factor for SUDEP.
Thirty-five percent of refractory epilepsy patients in our cohort had pOSA by oximetry, and an even higher 39% of patients had pOSA by either oximetry or one of the screening tools. The relatively high frequency of comorbid pOSA in our cohort is similar to prior studies of refractory epilepsy using polysomnography that reported OSA frequencies of 22%-30%. [18] [19] [20] Another study comparing polysomnographic variables between refractory and well-controlled epilepsy patients found that 20% of refractory epilepsy patients had an apnea-hypopnea index of >5/h, whereas no well-controlled epilepsy patient had OSA. 24 A limitation of our pilot study was lack of gold standard polysomnography for confirmation of OSA diagnosis, suggesting that the true frequency of OSA may have been even higher (because oximetric detection of mild OSA is variable, meaning our estimated frequency could be an underestimate). Few studies have evaluated the effect of continuous positive airway pressure (CPAP) therapy on seizure frequency and outcomes. However, several retrospective studies have found that OSA-epilepsy patients treated with CPAP were more likely to have a significant reduction in seizure frequency, or remain seizure-free at follow-up, when compared with OSA-epilepsy patients not treated with CPAP. 20, [25] [26] [27] Unsurprisingly, CPAP-compliant patients appear to have more significant reduction in seizure frequency when compared with noncompliant patients. 26 CPAP therapy also significantly reduced the frequency of interictal spikes compared with patients not using CPAP therapy, especially sleep-related spike frequency. 28 A single randomized-controlled pilot study has also suggested efficacy for CPAP therapy in reducing seizure burden in epilepsy. 29 Because previous evidence has suggested that treatment of comorbid OSA reduces seizure frequency, and given our findings of a possible association between OSA and heightened SUDEP risk profile, comorbid OSA should be identified early and treated in patients with epilepsy. Given the nocturnal predominance of SUDEP cases, it is possible that OSA may potentiate the proposed mechanisms of SUDEP. The majority of witnessed SUDEP cases involve a terminal seizure followed by apnea preceding a fatal arrhythmia. 11 Cardiac arrhythmias, one of the main proposed contributors to SUDEP, may be augmented by OSA. SCD, especially at night, has been associated with OSA in the general population without epilepsy, and may compound underlying autonomic dysfunction due to the comorbid seizure disorder. 13 Several mechanisms have been proposed, including nocturnal hypoxemia that may result in ventricular ectopy and arrhythmia. Obstructive apneas and hypopneas may lead to hypercapnia-induced sympathetic surges and hypoxemia that increases myocardial oxygen demand, resulting in cardiac ischemia and potentially fatal dysrhythmias. 13 Alternatively, the elevated sympathetic tone caused by chronic OSA may worsen ictal or postictal sympathetic surges, promoting tachyarrhythmias. 11, 30 OSA has been shown to increase the QTc interval, increasing the risk of SCD and SUDEP in vulnerable refractory epilepsy patients who may already have underlying prolonged QTc due to seizures or antiepileptic drug adverse effects. 31, 32 Finally, heart rate variability, a marker of autonomic function, was found to be decreased in patients with epilepsy (and also associated with higher SUDEP-7 scores), and if further impaired by OSA, could worsen poor preexisting underlying autonomic function in patients with epilepsy that favors development of tachydysrhythmias and sudden death. 33, 34 Respiratory dysfunction, another hypothesized mechanism for SUDEP, may also be worsened by OSA. Both ictal and periictal hypoxemia and hypercapnia secondary to central apnea have been reported in patients with partial and generalized epilepsy, promoted especially by prolonged focal seizures of temporal lobe origin and by generalized tonic-clonic seizures. [35] [36] [37] Seizure spread to the amygdala appears to be important in the pathogenesis of ictal apnea. 36 Serotonin receptors play an important role in ventilatory response to hypercapnia, and serotonin receptor dysfunction has been hypothesized to play a role in the pathogenesis of SUDEP. 38, 39 OSA patients have been shown to have chronic hypercapnia with a decreased ventilatory response to higher carbon dioxide levels, particularly at night. 40 As such, the combination of dysfunctional serotonin neurons and blunted respiratory response to hypercapnia caused by chronic OSA may further reduce respiratory drive following postictal apnea, increasing the likelihood of persistent hypoxia leading to fatal arrhythmia and death. Finally, OSA may contribute to SUDEP risk by increasing sleep fragmentation and resultant sleep deprivation, lowering the seizure threshold and increasing the risk for refractory seizures, status epilepticus, and seizure-related deaths. 41 Taken together, these findings highlight the importance of early identification and treatment of sleep apnea, not only to decrease the augmentation of autonomic and respiratory dysfunction underlying the pathogenesis of SUDEP, but also to reduce sleep fragmentation and deprivation, which in turn could directly reduce the risk of SUDEP by improving seizure control. 25, 26, 28 Our study has several limitations, including its small sample size drawn from a single tertiary referral center, making selection and referral biases possible, and its focus on refractory monitored epilepsy inpatients, potentially limiting generalizability to a broader population of epilepsy patients. In addition, we utilized the rSUDEP-7 risk profiling score as a surrogate for SUDEP risk, rather than the outcome of SUDEP itself; however, although the SUDEP-7 has not been directly validated in prospective studies, it was derived from one of the largest and best prospective studies of SUDEP risk factors, and has been previously used to assess risk status for association with candidate SUDEP biomarkers of heart rate variability and cerebral hypoxia. 5, 6, 9 Currently, well-validated SUDEP risk profiling tools for use in living epilepsy patients are lacking, and this research gap should be addressed by further large-scale population-based studies. Additional limitations of our study were that we relied on retrospectively estimated seizure frequency counts provided by patient report and ad hoc availability of seizure diaries, rather than prospectively recorded seizure frequency by patient seizure diaries and objective measures to estimate seizure burden, potentially leading to misestimation of seizure counts. Future prospective studies should assess seizure frequency to correlate with SUDEP risk. Additionally, a relatively small number of our patient subjects had generalized seizures within the previous year, potentially impacting rSUDEP-7 scores and future SUDEP risk. However, our study population drawn from the epilepsy monitoring unit is likely representative of refractory epilepsy patients who are at highest risk for SUDEP, with a relatively large number (11, 28%) of the sample having treatment-refractory epilepsy. Measurement of neck circumference was not available on all patients, so we utilized the STOP-BAG questionnaire rather than STOP-BANG. Because the association between pOSA and rSUDEP-7 was significant even in the absence of consideration of neck circumference or a greater number of patients having more frequent generalized seizures, it may have been that utilization of neck circumference measures and STOP-BANG would have resulted in an even stronger association. However, recent data suggest that the addition of neck circumference to the model may not have differed greatly, because in one recent study STOP-BANG and STOP-BAG did not differ significantly in the sensitivity and specificity for OSA diagnosis, so we believe the STOP-BAG model is likely sufficient for OSA diagnosis. 42 Additionally, given that this was a limited resource pilot study, we were unable to definitively diagnose OSA with polysomnography. These findings need to be confirmed by a larger, more definitive study in the epilepsy monitoring unit with polysomnography to better determine the true prevalence of OSA and the magnitude of association between OSA and SUDEP risk, and to explore possible mechanisms for SUDEP in at-risk refractory epilepsy patients including interictal, periictal, and ictal autonomic and respiratory alterations. We performed a post hoc sample size calculation to determine the number of subjects with epilepsy necessary to determine a similar frequency of OSA as determined by this pilot study utilizing instead the gold standard measure for OSA of polysomnography, and including community controls to prospectively ascertain additional markers for SUDEP risk status. Assuming a comparable frequency of OSA of 34.8% found in this pilot study utilizing oximetry measures, we would need approximately 25 epilepsy patients and 25 controls to detect a significant group difference in OSA assuming community-F I G U R E 2 Relationship between revised SUDEP Risk Inventory (rSUDEP-7) profile and adjusted oxyhemoglobin desaturation index (ODI). Shown is the association between SUDEP risk profile as indexed by scores on the rSUDEP-7, and the adjusted oxyhemoglobin desaturation index, where scores > 5/h are consistent with probable obstructive sleep apnea prevalent control OSA rates near 2%-4% with 80% power at an alpha level of 0.05. Assuming more conservative frequencies of OSA in epilepsy ranging from 25% to 34%, or a higher frequency of OSA in community controls between 5% and 12%, this would increase the sample size necessary to show significant group differences in OSA to between 27 and 80 subjects per group.
| CONCLUSION
Our pilot study reaffirms the high frequency of OSA in patients with epilepsy, finding that patients with pOSA were older and heavier, with more frequent focal epilepsy syndrome and a longer duration of epilepsy. Our data also demonstrate a possible association between pOSA and higher SUDEP risk profile. Future larger confirmatory studies with combined video-electroencephalography-polysomnography for more definitive identification of OSA, delineating its relationship to interictal and periictal hypoxia, hypercapnia, and autonomic function, are needed. Given the potential association between OSA, seizures, and SUDEP, patients with epilepsy should be screened and treated for OSA to reduce its impact on cardiorespiratory function and improve sleep consolidation.
